Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid Conjugates-Reference-Cited by-同舟云学术

Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid Conjugates

Published:2017-04-13 Issue:5 Volume:28 Page:1371-1381
ISSN:1043-1802
Container-title:Bioconjugate Chemistry
language:en
Short-container-title:Bioconjugate Chem.

Author:

Sun Xiuxia¹^ORCID,Ponte Jose F.¹,Yoder Nicholas C.¹,Laleau Rassol¹,Coccia Jennifer¹,Lanieri Leanne¹,Qiu Qifeng¹,Wu Rui¹,Hong Erica¹,Bogalhas Megan¹,Wang Lintao¹,Dong Ling¹,Setiady Yulius¹,Maloney Erin K.¹,Ab Olga¹,Zhang Xiaoyan¹,Pinkas Jan¹,Keating Thomas A.¹,Chari Ravi¹,Erickson Hans K.¹,Lambert John M.¹

Affiliation:

1. ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Pharmaceutical Science,Pharmacology,Biomedical Engineering,Bioengineering,Biotechnology

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.bioconjchem.7b00062

Reference26 articles.

1. Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer

2. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

3. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate